ArticleACS medicinal chemistry letters2012
Identification of Simple Compounds with Microtubule-Binding Activity That Inhibit Cancer Cell Growth with High Potency.
Article in ACS medicinal chemistry letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Review of ferroptosis in colorectal cancer: Friends or foes?World journal of gastroenterology · 2023Pooled it
- Reusable Pd/TiOMolecular diversity · 2026Article
- Exploiting metabolic cell death for cancer therapy.Nature reviews. Cancer · 2026Review
- AlClFrontiers in toxicology · 2025Article
- Ferroptosis in non-alcoholic liver disease: Molecular mechanisms and therapeutic implications.Frontiers in nutrition · 2023Review
- Deciphering the potential roles of ferroptosis in regulating tumor immunity and tumor immunotherapy.Frontiers in immunology · 2023Review
- Radical-Induced Cascade Annulation/Hydrocarbonylation for Construction of 2-Aryl-4Molecules (Basel, Switzerland) · 2022Article
- Molecular interactions at the colchicine binding site in tubulin: An X-ray crystallography perspective.Drug discovery today · 2022Review
- Epigenetic Regulation of Ferroptosis-Associated Genes and Its Implication in Cancer Therapy.Frontiers in oncology · 2022Review
- Design, Synthesis, and Biological Evaluation of Novel 1,3-Oxazole Sulfonamides as Tubulin Polymerization Inhibitors.ACS medicinal chemistry letters · 2021Article
- The Uniqueness of Clear Cell Renal Cell Carcinoma: Summary of the Process and Abnormality of Glucose Metabolism and Lipid Metabolism in ccRCC.Frontiers in oncology · 2021Review
- Dienone Compounds: Targets and Pharmacological Responses.Journal of medicinal chemistry · 2020Article
- Review
- Novel insights on targeting ferroptosis in cancer therapy.Biomarker research · 2020Review
- Access to highly substituted oxazoles by the reaction of α-azidochalcone with potassium thiocyanate.Beilstein journal of organic chemistry · 2020Article
- The Latest View on the Mechanism of Ferroptosis and Its Research Progress in Spinal Cord Injury.Oxidative medicine and cellular longevity · 2020Review
- Ferroptosis, a new form of cell death, and its relationships with tumourous diseases.Journal of cellular and molecular medicine · 2017Review
- The Role of Ferroptosis in Cancer Development and Treatment Response.Frontiers in pharmacology · 2017Review
- Ferroptosis: process and function.Cell death and differentiation · 2016Review
- Human Haploid Cell Genetics Reveals Roles for Lipid Metabolism Genes in Nonapoptotic Cell Death.ACS chemical biology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
We analyzed more than 1 million small molecules with the goal of finding simple synthetic compounds that potently inhibit cancer cell growth. We identified three such compounds with unknown mechanisms of action. Subsequent studies revealed that all three of these small molecules target microtubules. These three scaffolds can serve as templates for developing new microtubule-targeted agents, overcoming the limits of existing microtubule-inhibiting drugs derived from complex natural products.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.